BPC-157 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-02-16. Anything still debated is marked as such rather than presented as settled.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence is GEPPPGKPADDAGLV. Its name derives from the phrase body protection compound, a term applied to a protein fraction originally detected in human gastric juice. The short peptide is not that full protein; it corresponds to a stable fragment of the larger molecule. Researchers frequently describe it as a pentadecapeptide because it contains exactly fifteen residues. Its neutral molecular mass is approximately 1419 daltons.
The sequence places several glycine and proline residues near the middle, which may influence how the chain folds in solution. The peptide is linear rather than cyclic, and it carries no disulfide bridges. Commercial material is commonly supplied as the acetate salt, although the free base and other counterion forms also appear. Because the term BPC-157 refers to a specific sequence, samples with slight sequence variants are chemically different substances. Published work generally treats the fifteen-residue sequence as the defining structure.
Physical descriptions in supplier documents and papers usually list the compound as a white to off-white powder. It dissolves readily in water and in common aqueous buffers, and solutions are often prepared fresh before an experiment. Molecular mass near 1419 daltons helps verify identity during mass spectrometry. The powder is somewhat hygroscopic, so moisture exposure can alter the measured mass of a sample. Purity is typically reported as a percentage from chromatographic analysis.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic pentadecapeptide | Composed of fifteen amino acid residues |
| Amino acid sequence | Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val | Single-letter form GEPPPGKPADDAGLV |
| Original source | Fragment of a protein in human gastric juice | First characterized in the 1990s |
| Number in name | 157 | Refers to the fragment's position in the source protein |
| Human trial evidence | Limited | Preclinical rodent data predominate |
BPC-157 is a synthetic pentadecapeptide whose sequence is commonly given as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described in the literature as a fragment of a larger protein found in human gastric juice, referred to as body protection compound. The peptide was first characterized in the early 1990s by a research group in Zagreb, Croatia. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Supplied material is typically a lyophilized white to off-white powder. The peptide is freely soluble in water and in common aqueous buffers, which allows it to be handled as a stock solution. Because the sequence contains no cysteine, disulfide cross-linking is not a route of degradation. The absence of aromatic residues means ultraviolet absorbance at 280 nm is minimal, so quantification usually relies on peptide bond absorbance near 214 nm or on amino acid analysis.
The molecule carries 15 residues, a molar mass near 1419.5 g/mol, and the formula C62H98N16O22. Its structure features a proline-rich central region, a pair of adjacent aspartic acid residues, and no cysteine. The absence of cysteine means no disulfide bonds can form, which simplifies refolding and reconstitution. Suppliers usually ship the material as a freeze-dried powder that appears white to off-white. It dissolves readily in water and in saline solutions.
Published storage guidance follows general peptide practice rather than product-specific studies. The dry powder is typically kept at minus 20 degrees Celsius, away from light and moisture. Once reconstituted, solutions are generally refrigerated and used over days to weeks, because the aqueous environment slowly promotes hydrolysis and oxidation. Long-term data on degradation rates or breakdown products are sparse. Stated shelf lives from different producers vary widely, reflecting the absence of a shared reference standard.
=== Economics === In the US, generic methadone tablets are inexpensive, with retail prices ranging from $0.25 to $2.50 per defined daily dose. Methadone maintenance clinics in the US may be covered by private insurance, Medicaid, or Medicare. Medicare covers methadone under the prescription drug benefit, Medicare Part D, when it is prescribed for pain, but not when it is used for opioid dependence treatment because it cannot be dispensed in a retail pharmacy for this purpose. In California methadone maintenance treatment is covered under the medical benefit. Patients' eligibility for methadone maintenance treatment is most often contingent on them being enrolled in substance abuse counseling. People on methadone maintenance in the US either have to pay cash or if covered by insurance must complete a pre-determined number of hours per month in therapeutic groups or counseling. The United States Department of Veteran's Affairs (VA) Alcohol and Drug Dependence Rehabilitation Program offers methadone services to eligible veterans enrolled in the VA health care system. Methadone maintenance treatment (MMT) cost analyses often compare the cost of clinic visits versus the overall societal costs of illicit opioid use. A preliminary cost analysis conducted in 2016 by the US Department of Defense determined that methadone treatment, which includes psychosocial and support services, may cost an average of $126.00 per week or $6,552.00 per year.
== Research == In 2015, Merck reported results in thirteen cancer types; much attention was given to early results in head and neck cancer. As of May 2016, pembrolizumab was in phase IB clinical trials for triple-negative breast cancer (TNBC), gastric cancer, urothelial cancer, and head and neck cancer (all under the "Keynote-012" trial) and in phase II trial for TNBC (the "Keynote-086" trial). At ASCO, in June 2016, Merck reported that the clinical development program was directed to around 30 cancers and that it was running over 270 clinical trials (around 100 in combination with other treatments) and had four registration-enabling studies in process. Results of a phase III clinical trial in triple-negative breast cancer were reported in October 2019. Results of a phase II clinical trial in Merkel-cell carcinoma were reported in June 2016. Results of a clinical trial in people with untreatable metastases arising from various solid tumors were reported in 2017. A clinical phase III trial in combination with epacadostat, an Indoleamine 2,3-dioxygenase (IDO1) inhibitor to treat melanoma was completed in 2019. In 2021, researchers reported the results of a five-year follow-up study. In January 2022, a combination clinical trial of pembrolizumab and NL-201, a de novo protein undergoing a phase I clinical trial in people with advanced, relapsed or refractory solid tumors. In March 2023, Merck reported the results of NRG-GY018, a phase III clinical trial in people with stage three to four or recurrent endometrial carcinoma.
Barbiturates (e.g., pentobarbital, sodium thiopental) – non-selective Ethanol – non-selective Inhalational anaesthetics (e.g., cyclopropane, enflurane, halothane, isoflurane, sevoflurane) – non-selective GYKI-52466 Irampanel Perampanel Talampanel PEP1-TGL : GluA1 subunit C-terminus peptide analog that inhibits AMPA receptor incorporation to the postsynaptic density
Sources: en.wikipedia.org
The second Romanian principality, Moldavia, achieved full autonomy during the reign of Bogdan I around 1360. A local dynasty ruled the Despotate of Dobruja in the second half of the 14th century, but the Ottoman Empire took possession of the territory after 1388. Princes Mircea I and Vlad III of Wallachia, and Stephen III of Moldavia defended their countries' independence against the Ottomans. Most Wallachian and Moldavian princes paid a regular tribute to the Ottoman sultans from 1417 and 1456, respectively. John Hunyadi, organised the defence of the Kingdom of Hungary and anti-Ottoman campaigns from 1440 until his death in 1456. Increasing taxes outraged the Transylvanian peasants, and they rose up in an open rebellion in 1437, but the Hungarian nobles and the heads of the Saxon and Székely communities jointly suppressed their revolt. The formal alliance of the Hungarian, Saxon, and Székely leaders, known as the Union of the Three Nations, became an important element of the self-government of Transylvania. The Orthodox Romanian knezes ("chiefs") were excluded from the Union.
The toxic action of mHTT may manifest and produce the HD pathology through multiple cellular changes. In its mutant (polyglutamine expanded) form, the protein is more prone to cleavage that creates shorter fragments containing the polyglutamine expansion. These protein fragments have a propensity to undergo misfolding and aggregation, yielding fibrillar aggregates in which non-native polyglutamine β-strands from multiple proteins are bonded together by hydrogen bonds. These aggregates share the same fundamental cross-beta amyloid architecture seen in other protein deposition diseases. The aggregates are covered on their surface with a 'fuzzy coat' that contains non-polyglutamine parts of the protein, as illustrated in a published structural model shown above. Over time, the aggregates accumulate to form inclusion bodies within cells, ultimately interfering with neuronal function. Inclusion bodies have been found in both the cell nucleus and cytoplasm. Inclusion bodies in cells of the brain are one of the earliest pathological changes, and some experiments have found that they can be toxic for the cell, but other experiments have shown that they may form as part of the body's defense mechanism and help protect cells. Several pathways by which mHTT may cause cell death have been identified.
Subdural fluid collections Enhancement of the meninges Engorgement of venous structures Pituitary swelling Sagging of the brain For suspected spinal CSF leaks, spine imaging can be used to guide treatment.
Sources: en.wikipedia.org
===== Research ===== In 2016, a study from the University of Nottingham was published describing the first synthetic spider silk that is functionally identical to naturally spun spider silk. Using non-natural methionine analog L-azidohomoalanine (L-Aha) and genetically modified E-Coli cells, self-assembling proteins under the conditions needed to create the filament were produced. These conditions had been researched years earlier by J. Johansson and co-workers studying the production of spider silk proteins. The proteins used in the study are a miniaturized version of the silk monomers found in nature that behave the same way; because of the modifications, they were able to express functionalized regions of the protein 4RepCT, which is a self-assembling recombinant dragline silk protein, derived from the nursery-web spider along the axis of the filament.
=== Sentinox === On 27 October 2021, Applied Pharma Research (APR), a wholly owned subsidiary of Relief, announced positive interim data from its clinical trial of Sentinox, a nasal spray aimed at reducing the viral load of patients with COVID-19, in-turn reducing the transmissibility of the virus.
Bektashism originated in Anatolia as the followers of the 13th-century scholar Bektash, who himself studied under the mystic Ahmad Yasawi, who was born in Sayram, now in southern Kazakhstan. The doctrines and rituals of the Bektashis were codified by the mystic Balım Sultan, who is considered the pīr-i thānī (“the Second Elder”) by Bektashis. It was originally founded as a Sufi movement, one of many Sufi orders within Sunni Islam. By the 16th century, the order had adopted some tenets of Twelver Shi'ism—including veneration of Ali, the cousin and son-in-law of the Islamic prophet Muhammad, and the Twelve Imams—as well as a variety of syncretic beliefs.
There is debate as to whether the Kingdom of Poland, as a state, was formally replaced by the Vistula Land. Towns were stripped of their charters in reprisal and turned into villages. The Russian Partition of Poland was made an official province of the Russian Empire in 1867. In the early 20th century, a major part of the Russian Revolution of 1905 was the Revolution in the Kingdom of Poland (1905–1907). The return to Poland's independence was a result of the First World War on the Polish lands (1914–1918), the overthrow of the Tsarist regime, and the defeat of the Central Powers in 1918.
Sources: en.wikipedia.org
It is a chain of fifteen amino acids, referred to as a pentadecapeptide. The sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It corresponds to a fragment of a protein found in human gastric juice.
It is neither a naturally circulating hormone nor an approved medicine in most countries. It is a synthetic peptide fragment used chiefly as a laboratory research material. Its regulatory status varies by jurisdiction, and it is not authorized as a therapeutic product in the United States or the European Union.
Published human evidence is very limited. Most findings come from rodent studies conducted by a small number of groups. As a result, statements about its effects in humans are generally described as uncertain rather than established.
The letters BPC stand for body protection compound. The number 157 refers to a specific fragment designation from early work on gastric proteins. The full name is a label for a synthetic fifteen-amino-acid peptide rather than a naturally isolated drug.